Myopathy Clinical Trial
Official title:
A Comparative Study of Strategies for Management of Duchenne Myopathy in Assiut University Children Hospital
1. Comparing different lines of treatment of Duchenne Myopathy (DM) and assessment of new
lines of treatment (mesenchymal stem cell, phosphodiesterase inhibitors) in reducing the
impact of disability in the patients with Duchenne Myopathy and slowing the progression
of cardiomyopathy
2. Upsetting and implementation of the best treatment plan for those children with Duchenne
myopathy which is suitable for the available resources in Assiut University Children
Hospital
Status | Not yet recruiting |
Enrollment | 45 |
Est. completion date | November 2021 |
Est. primary completion date | September 2021 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 5 Years to 15 Years |
Eligibility |
Inclusion Criteria: - Diagnosis of DMD confirmed by electromyogram (EMG) , Creatine phosphokinase (CPK) level and/ or DNA analysis or muscle biopsy. - Male patients - Age 5-15y. - Ambulatory (loss of ambulation was only seen in those with baseline 6 Minute Walk Distance {6MWD} <325 meters.) - No clinical evidence of heart failure. Exclusion Criteria: - Female patients - Any injury which may impact functional testing, e.g. upper or lower limb fracture. - hypertension, diabetes, - Wheelchair bound. - Cardiac rhythm disorder, specifically: rhythm other than sinus, supraventricular tachycardia (SVT), atrial fibrillation, ventricular tachycardia.or heart failure (left ventricle ejection fraction {LVEF < 50%}. - Continuous ventilatory support. - Liver disease (acute, chronic liver disease) - Renal impairment |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Emery AE. The muscular dystrophies. Lancet. 2002 Feb 23;359(9307):687-95. Review. — View Citation
Fukudome T, Shibuya N, Yoshimura T, Eguchi K. Short-term effects of prednisolone on neuromuscular transmission in the isolated mdx mouse diaphragm. Tohoku J Exp Med. 2000 Nov;192(3):211-7. Erratum in: Tohoku J Exp Med. 2004 Aug;203(4):359. — View Citation
Galli R, Borello U, Gritti A, Minasi MG, Bjornson C, Coletta M, Mora M, De Angelis MG, Fiocco R, Cossu G, Vescovi AL. Skeletal myogenic potential of human and mouse neural stem cells. Nat Neurosci. 2000 Oct;3(10):986-91. — View Citation
Heslop L, Morgan JE, Partridge TA. Evidence for a myogenic stem cell that is exhausted in dystrophic muscle. J Cell Sci. 2000 Jun;113 ( Pt 12):2299-308. — View Citation
Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell. 2012 Jun 14;10(6):709-16. doi: 10.1016/j.stem.2012.05.015. Review. Erratum in: Cell Stem Cell. 2012 Jul 6;11(1):136. — View Citation
Khan MA. Corticosteroid therapy in Duchenne muscular dystrophy. J Neurol Sci. 1993 Dec 1;120(1):8-14. Review. — View Citation
Kojima S, Takagi A, Watanabe T. [Effect of prednisolone on apoptosis and cellular infiltration in mdx mouse muscle]. Rinsho Shinkeigaku. 1999 Nov;39(11):1109-13. Japanese. — View Citation
Lapidos KA, Kakkar R, McNally EM. The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res. 2004 Apr 30;94(8):1023-31. Review. — View Citation
Mendell JR, Clark KR. Challenges for gene therapy for muscular dystrophy. Curr Neurol Neurosci Rep. 2006 Jan;6(1):47-56. Review. — View Citation
Mercuri E, Muntoni F. Muscular dystrophies. Lancet. 2013 Mar 9;381(9869):845-60. Review. — View Citation
Nallamilli BR, Ankala A, Hegde M. Molecular diagnosis of Duchenne muscular dystrophy. Curr Protoc Hum Genet. 2014 Oct 1;83:9.25.1-29. doi: 10.1002/0471142905.hg0925s83. — View Citation
Partridge TA. Stem cell therapies for neuromuscular diseases. Acta Neurol Belg. 2004 Dec;104(4):141-7. Review. — View Citation
Price FD, Kuroda K, Rudnicki MA. Stem cell based therapies to treat muscular dystrophy. Biochim Biophys Acta. 2007 Feb;1772(2):272-83. Epub 2006 Sep 6. Review. — View Citation
Qu-Petersen Z, Deasy B, Jankowski R, Ikezawa M, Cummins J, Pruchnic R, Mytinger J, Cao B, Gates C, Wernig A, Huard J. Identification of a novel population of muscle stem cells in mice: potential for muscle regeneration. J Cell Biol. 2002 May 27;157(5):851-64. Epub 2002 May 20. — View Citation
Shafritz DA, Oertel M, Menthena A, Nierhoff D, Dabeva MD. Liver stem cells and prospects for liver reconstitution by transplanted cells. Hepatology. 2006 Feb;43(2 Suppl 1):S89-98. Review. — View Citation
Toma JG, Akhavan M, Fernandes KJ, Barnabé-Heider F, Sadikot A, Kaplan DR, Miller FD. Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nat Cell Biol. 2001 Sep;3(9):778-84. — View Citation
Wang YX, Rudnicki MA. Satellite cells, the engines of muscle repair. Nat Rev Mol Cell Biol. 2011 Dec 21;13(2):127-33. doi: 10.1038/nrm3265. Review. — View Citation
Wong BL, Christopher C. Corticosteroids in Duchenne muscular dystrophy: a reappraisal. J Child Neurol. 2002 Mar;17(3):183-90. Review. — View Citation
* Note: There are 18 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 6 Minute Walk Distance (6MWD) | It is used as measure of motor strength in patients with Duchenne Myopathy. A baseline 6MWD of <350 meters was associated with greater functional decline, and loss of ambulation was only seen in those with baseline 6MWD <325 meters | 6 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06374719 -
WiTNNess - TNNT1 Myopathy Natural History Study
|
||
Enrolling by invitation |
NCT02235220 -
Reduction of Masticatory Muscle Activity by Restoring Canine Guidance
|
N/A | |
Terminated |
NCT00278564 -
Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases
|
Phase 1 | |
Completed |
NCT01642056 -
EPI-743 for Metabolism or Mitochondrial Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02011282 -
Electro-Neuro-Muscular Stimulation in ICU
|
N/A | |
Completed |
NCT01702987 -
Evaluation of Ubiquinol on Mitochondrial Oxidative Capacity in Statin Patients Using 31PMRS
|
N/A | |
Active, not recruiting |
NCT01225614 -
Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive
|
Phase 3 | |
Recruiting |
NCT03749538 -
Acute Transcranial Direct Current Stimulation in Patients With Systemic Autoimmune Myopathies
|
N/A | |
Completed |
NCT02442986 -
Neurological Outcome in Surgical and Non-surgical Septic Patients
|
N/A | |
Recruiting |
NCT01022450 -
Study of the Causes of the Breakdown of Muscle Fibers in Hospitalized Patients
|
N/A | |
Withdrawn |
NCT00990834 -
Muscle Characteristics Associated With Statin Therapy
|
N/A | |
Active, not recruiting |
NCT00937001 -
Critical Illness Myopathy as a Cause of Debilitating ICU-Acquired Weakness
|
N/A | |
Recruiting |
NCT01353430 -
Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD)
|
||
Completed |
NCT03751644 -
Peripherical Neuromuscular Electrical Stimulation in Systemic Autoimmune Myopathies
|
N/A | |
Completed |
NCT02765828 -
Identification of Tongue Involvement in Late-Onset Pompe Disease
|
||
Recruiting |
NCT05599568 -
Repeated Bout Effect i Neuromuscular Diseases
|
N/A | |
Withdrawn |
NCT02124070 -
Therapeutic Effect of Recombinant Human Growth Hormone (rhGH) on the Myopathy of Cystinosis
|
Phase 1/Phase 2 | |
Completed |
NCT02706314 -
Impact of Human Blood Serum From Critically Ill Patients on Human Colon Neuronal Networks.
|
||
Recruiting |
NCT03042286 -
SAPhIRE Statin Adverse Drug Reaction
|
||
Not yet recruiting |
NCT04941079 -
Safety and Efficacy of Inactivated SARS-CoV-2 Vaccine in Immune-related Myopathy (Myasthenia Gravis and Inflammatory Myopathy) Patients :a Prospective Observational Study
|